Andrea Charles | 05/30/2013
In this exclusive interview Tobias Noeske, Associate Principal Scientist from AstraZeneca, speaks to Andrea Charles from Pharma IQ. Noeske describes how AstraZeneca are reducing compound attrition rates arising from drug-induced liver injury (DILI). DILI is a major cause for attrition in clinical trials, which can cost hundreds of million of dollars in the late stages of drug development.
Noeske explains how in silico models can identify and mitigate compound-related safet...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma & Health 2024
September 10 - 12, 2024
Düsseldorf, Germany
Register Now |
View Agenda |
Learn More
Temperature Control and Logistics North America Summit
September 10 - 12, 2024
Falls Church, VA
Register Now |
View Agenda |
Learn More